SAN DIEGO–(BUSINESS WIRE)–Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Sales of $283.7 million worldwide, including $191.0 million in the United States (U.S.) Gross margin of 57%, up 270 basis points compared to third quarter 2025 Pump shipments of approximately 33,000 worldwide, including nearly 23,000 pu
